[Therapeutic implications of ocular involvement in systemic degenerative diseases].
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002830:Choroid Neoplasms / Q000556:secondary; D003231:Conjunctivitis / Q000209:etiology; D005128:Eye Diseases / Q000209:etiology* / Q000628:therapy; D005134:Eye Neoplasms / Q000556:secondary*; D006105:Granulomatous Disease, Chronic / Q000150:complications* / Q000276:immunology / Q000628:therapy; D006801:Humans; D007634:Keratitis / Q000209:etiology; D007938:Leukemia / Q000150:complications* / Q000628:therapy; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000628:therapy; D009504:Neutrophils / Q000276:immunology; D009886:Ophthalmoplegia / Q000209:etiology; D012164:Retinal Diseases / Q000209:etiology
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents
Implicazioni terapeutiche della compromissione oculare in malattie degenerative sistemiche.